Gregory Michael Cote

This study shows DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells, reducing ATR inhibitor efficacy, and suggests combining ATR and DNA-PK inhibition could enhance treatment in such cancers.

The paper identifies a dynamic microRNA profile associated with chemotherapy resistance in osteosarcoma and predicts novel therapeutic targets that could reverse resistance.

This study identifies DNA methylation subtypes in osteosarcoma that predict clinical outcomes and response to chemotherapy.

The paper identifies microRNA-mRNA networks associated with prognosis in osteosarcoma and validates their predictive value across independent datasets.

The paper develops a multi-gene signature predicting PARP inhibitor response across cancer types using machine learning and validates it in vitro and in clinical datasets.